Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK To Seek Only Limited Regulatory Alignment With EU

Pharma Industry Calls For ‘Ambition And Pragmatism’

Executive Summary

Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.

You may also be interested in...



UK's Post-Brexit Medicine Plans Under Pressure

UK proposals for limited cooperation with the EU in medicines regulation, including the recognition of certificates and inspections, are one glimmer of light in an otherwise uncertain post-Brexit regulatory scenario for the UK. But time pressures and political spats over the future relationship could throw the whole enterprise into doubt. 

UK-US Free Trade Deal Plans Disappoint Industry

The UK has published its negotiating mandate for talks on a free trade deal with the US. As expected, intellectual property protection figures prominently, but the life sciences industry sees little merit in the government’s approach. It also warns that the UK’s future relationship with the EU could lead to greater regulatory burdens and costs.

Industry ‘Disappointed’ By UK Plans For Free Trade Deal With US

The UK has published its negotiating mandate for talks on a free trade deal with the US. As expected, intellectual property protection figures prominently, but the life sciences industry sees little merit in the government’s approach. It also warns that the UK’s future relationship with the EU could lead to greater regulatory burdens and costs.

Related Content

Topics

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel